اثرات میواینوزیتول خوراکی بر کیفیت اسپرم در مردان مبتلا به اولیگواستنوتراتوزوسپرمیا: متاآنالیز

نوع مقاله : مروری

نویسندگان

1 کارشناس ارشد مامایی، دانشکده پرستاری و مامایی، علوم پزشکی مشهد، دانشگاه آزاد اسلامی، مشهد، ایران.

2 دانشجوی دکتری بهداشت باروری، گروه مامایی و بهداشت باروری، دانشکده پرستاری و مامایی، دانشگاه علوم پزشکی مشهد، مشهد، ایران. گروه پرستاری و مامایی، علوم پزشکی مشهد، دانشگاه آزاد اسلامی، مشهد، ایران.

3 استادیار گروه پزشکی اجتماعی، دانشکده پزشکی، دانشگاه علوم پزشکی مشهد، دانشگاه آزاد اسلامی، مشهد، ایران.

10.22038/ijogi.2025.87836.6430

چکیده

مقدمه: اولیگواستنوتراتوزواسپرمی (OAT) یکی از شایع‌ترین عوامل ناباروری مردان است که باعث تغییرات قابل توجه در پارامترهای اسپرم می‌شود. افزایش تولید رادیکال‌های آزاد اکسیژن (ROS) می‌تواند منجر به آسیب سلولی و کاهش باروری گردد. میواینوزیتول (MYO) می‌تواند بهبود بخشی از پارامترهای اسپرم را فراهم کرده و اثرات منفی ROS را کاهش دهد، بنابراین مطالعه حاضر با هدف بررسی اثربخشی ترکیبات حاوی میواینوزیتول بر پارامترهای اسپرم در مردان مبتلا به OAT انجام شد.
روش‌کار: جستجوی سیستماتیک در پایگاه‌های اطلاعاتی PubMed، Scopus، Web of Science، Cochrane، SID و Google Scholar با استفاده از کلمات کلیدی فارسی (ناباروری مردان، میواینوزیتول، کیفیت اسپرم، تحرک اسپرم، کارآزمایی تصادفی کنترل‌شده، متاآنالیز) و انگلیسی شامل Male Infertility، Myo-Inositol،Sperm Quality، Sperm Motility، Randomized Controlled Trial، Meta-Analysis با به‌کارگیری عملگرهای بولی AND و OR طراحی شد. تجزیه و تحلیل داده‌ها با استفاده از نرم‌افزار Egger انجام شد. برای بررسی همگنی مطالعات از آزمون Cochran و شاخص I² استفاده گردید.
یافته ­ها: از مجموع 23،250 مقاله شناسایی شده، ۱۰ مقاله وارد مطالعه شدند که از این میان، ۴ مقاله قابلیت ورود به متاآنالیز را داشتند. تحلیل‌ها با استفاده از مدل اثر ثابت نشان داد که مصرف میواینوزیتول با افزایش معنی‌دار پارامترهای اسپرم همراه است؛ به‌طوری‌که تحرک اسپرم (اندازه اثر: 66/2 فاصله اطمینان 95%: 58/0 تا 73/4)، میزان تحرک پیش‌رونده (اندازه اثر: 20/3 فاصله اطمینان 95%: 44/1 تا 96/4)، غلظت اسپرم (اندازه اثر: 93/3 فاصله اطمینان 95%: 64/2 تا 41/5) و مورفولوژی اسپرم (اندازه اثر: 19/6 فاصله اطمینان 95%: 63/5 تا 75/6) بود.
نتیجه ­گیری: یافته‌ها نشان می‌دهند که مصرف میواینوزیتول می‌تواند بهبود قابل توجهی در پارامترهای اسپرم و باروری مردان مبتلا به OAT ایجاد کند و به‌عنوان یک مکمل مؤثر در درمان ناباروری مردان OAT مورد استفاده قرار گیرد.

کلیدواژه‌ها

موضوعات

عنوان مقاله [English]

The Effects of Oral Myo-Inositol on Sperm Quality in Men with Oligoasthenoteratozoospermia: A Meta-Analysis

نویسندگان [English]

  • Fahimeh Tahonian Golkhatmi 1
  • Dina Abadi Bavil 2
  • Mojtaba Meshkat 3
1 M.Sc. of Midwifery, School of Nursing and Midwifery, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.
2 PhD Student of Reproductive Health, Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran. Department of Nursing and Midwifery, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.
3 Assistant Professor, Department of Community Medicine, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.
چکیده [English]

Introduction: Oligoasthenoteratozoospermia (OAT) is one of the most common causes of male infertility, leading to significant alterations in sperm parameters. Increased production of reactive oxygen species (ROS) can cause cellular damage and reduce fertility. Myo-inositol (MYO) has been suggested to improve certain sperm parameters and mitigate the negative effects of ROS. This study was conducted with aim to evaluate the efficacy of myo-inositol-containing supplements on sperm parameters in men with OAT.
Methods: A systematic search was conducted in Magiran, PubMed, Scopus, Web of Science, Cochrane, SID, and Google Scholar databases using Persian and English keywords (Male Infertility, Myo-Inositol, Sperm Quality, Sperm Motility, Randomized Controlled Trial, Meta-Analysis) and keywords with Boolean operators AND/OR. Data analysis was performed using Egger software. Heterogeneity among studies was assessed using Cochran’s Q test and the I² index.
Results: Out of 23.250 identified articles, 10 studies entered the study, and among them, 4 studies were eligible for meta-analysis. The analysis using fixed-effect model showed that myo-inositol supplementation was associated with significant improvements in sperm parameters: sperm motility (effect size: 2.66; 95% CI: 0.58–4.73), progressive motility (3.20; 1.44–4.96), sperm concentration (3.93; 2.64–5.41), and sperm morphology (6.19; 5.63–6.75).
Conclusion: The findings indicate that myo-inositol supplementation can significantly improve sperm parameters and male fertility in men with OAT, supporting its potential use as an effective adjunct in the management of male infertility associated with OAT.

کلیدواژه‌ها [English]

  • Infertility
  • Inositol
  • Male Fertility
  • Sperm Motility

مراجع

  1. Zolfaghar-Khani M, Majidi H, Feizzadeh B, Sabaghi M. Diagnostic accuracy of resistive index of capsular and intratesticular branches of testicular arteries in infertile men with oligoasthenospermia: A case-control study. BioMedicine 2020; 10(4):18.
  2. Alahmar AT, Singh R. Comparison of the effects of coenzyme Q10 and Centrum multivitamins on semen parameters, oxidative stress markers, and sperm DNA fragmentation in infertile men with idiopathic oligoasthenospermia. Clinical and Experimental Reproductive Medicine 2022; 49(1):49.
  3. Wang Y, Zhang R, Pan W, Xu Z, Yang H, Luo Q, et al. Effects of L-carnitine combined with pancreatic kininogenase on thioredoxin 2, thioredoxin reductase 1, and sperm quality in patients with oligoasthenospermia. Translational Andrology and Urology 2021; 10(8):3515.
  4. Elekima I, Aworu AM, Brown H, Brisibe N, George-Opuda IM, Waribo HA, et al. Evidence-based assessment of male-only infertility: prevalence and associated risk factors in Port Harcourt metropolis, Rivers State, Nigeria. International Journal of Research in Medical Sciences 2023; 11(12):4285.
  5. Guyansyah A, Wratsangka R, Dhanardono D, Ghazali MF, Edy HJ, Widyatama HG, et al. Primary infertility of male and female factors, polycystic ovary syndrome and oligoasthenoteratozoospermia dominate the infertile population in agricultural and industrial areas in Karawang Regency, West Java Province, Indonesia. Bali Medical Journal 2021; 10(1):167-73.
  6. Wang Z, Zhou Z, Zhang L, Li X, Li M, Pan Y, et al. Efficacy and safety of nonpharmacological strategies for the treatment of oligoasthenospermia: a systematic review and Bayesian network meta-analysis. European Journal of Medical Research 2023; 28(1):6.
  7. Parivar K, Nasr EM, Hayati RN. Evaluation of Sperm Quality and Oxidative Stress Level in Asthenoteratozoospermia Men by N-Acetylcysteine Treatment. Journal of Plasma and Biomarkers 2020; 13(2):27-38.
  8. Mirończuk-Chodakowska I, Witkowska AM, Zujko ME. Endogenous non-enzymatic antioxidants in the human body. Advances in medical sciences 2018; 63(1):68-78.
  9. Nouri M. Correlation between dietary antioxidant intake and sperm parameters in infertile men with oligozoospermia. Qom University of Medical Sciences Journal 2019; 13(5):9-18.
  10. Mohammadi F, Varanloo N, Heydari Nasrabadi M, Vatannejad A, Amjadi FS, Javedani Masroor M, et al. Supplementation of sperm freezing medium with myoinositol improve human sperm parameters and protects it against DNA fragmentation and apoptosis. Cell and Tissue Banking 2019; 20(1):77-86.
  11. Artini PG, Casarosa E, Carletti E, Monteleone P, Di Noia A, Di Berardino OM. In vitro effect of myo-inositol on sperm motility in normal and oligoasthenospermia patients undergoing in vitro fertilization. Gynecological Endocrinology 2017; 33(2):109-12.
  12. Condorelli RA, La Vignera S, Di Bari F, Unfer V, Calogero AE. Effects of myoinositol on sperm mitochondrial function in-vitro. Eur Rev Med Pharmacol Sci 2011; 15(2):129-34.
  13. Condorelli RA, Barbagallo F, Calogero AE, Cannarella R, Crafa A, La Vignera S. D-chiro-inositol improves sperm mitochondrial membrane potential: In vitro evidence. Journal of Clinical Medicine 2020; 9(5):1373.
  14. Rahavi A, Haidari AA, Khalili MA, Ghasemzadeh J, Tabibnejad N. The correlation between reactive oxygen species and leukocytes in normozoospermia and oligoasthenoteratozoospermia ejaculates. Journal of Mazandaran University of Medical Sciences 2008; 18(63):91-9.
  15. Abdolsamadi M, Mohammadi F, Nashtaei MS, Teimouri M, Sardar R, Dayani M, et al. Does myoinositol supplement improve sperm parameters and DNA integrity in patients with oligoasthenoteratozoospermia after the freezing–thawing process?. Cell and Tissue Banking 2020; 21(1):99-106.
  16. Ghasemi A, Amjadi F, Mirsaeed SM, Beigi RM, Ghasemi S, Moradi Y, et al. The effect of Myo-inositol on sperm parameters and pregnancy rate in oligoasthenospermic men treated with IUI: A randomized clinical trial. International Journal of Reproductive Biomedicine 2019; 17(10):749.
  17. Ghaemi M, Seighali N, Shafiee A, Beiky M, Kohandel Gargari O, Azarboo A, et al. The effect of Myo‐inositol on improving sperm quality and IVF outcomes: A systematic review and meta‐analysis. Food science & nutrition 2024; 12(11):8515-24.
  18. Michaelsen MP, Poulsen M, Bjerregaard AA, Borgstrøm M, Poulsen LK, Chortsen MB, et al. The Effect of Dietary Supplements on Male Infertility in Terms of Pregnancy, Live Birth, and Sperm Parameters: A Systematic Review and Meta-Analysis. Nutrients 2025; 17(10):1710.
  19. Dinkova A, Martinov D, Konova E. Efficacy of myo-inositol in the clinical management of patients with asthenozoospermia. European Review for Medical & Pharmacological Sciences 2017; 21.
  20. Canepa P, Dal Lago A, De Leo C, Gallo M, Rizzo C, Licata E, et al. Combined treatment with myo-inositol, alpha-lipoic acid, folic acid and vitamins significantly improves sperm parameters of sub-fertile men: a multi-centric study. European Review for Medical & Pharmacological Sciences 2018; 22(20).
  21. Capece M, Romeo G, Ruffo A, Romis L, Mordente S, Di Lauro G. A phytotherapic approach to reduce sperm DNA fragmentation in patients with male infertility. Urologia Journal 2017; 84(2):79-82.
  22. De Leo V, Tosti C, Morgante G, Ponchia R, Luddi A, Governini L, et al. Positive effect of a new combination of antioxidants and natural hormone stimulants for the treatment of oligoasthenoteratozoospermia. Journal of clinical medicine 2022; 11(7):1991.
  23. Vander Borght M, Wyns C. Fertility and infertility: Definition and epidemiology. Clinical biochemistry 2018; 62:2-10.
  24. Calogero AE, Aversa A, La Vignera S, Corona G, Ferlin A. The use of nutraceuticals in male sexual and reproductive disturbances: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS). Journal of endocrinological investigation 2017; 40(12):1389-97.
  25. Duca Y, Calogero AE, Cannarella R, Condorelli RA, La Vignera S. Current and emerging medical therapeutic agents for idiopathic male infertility. Expert opinion on pharmacotherapy 2019; 20(1):55-67.
  26. Smits RM, Mackenzie‐Proctor R, Yazdani A, Stankiewicz MT, Jordan V, Showell MG. Antioxidants for male subfertility. Cochrane Database of Systematic Reviews; 2019(3).
  27. Amorini AM, Listorti I, Bilotta G, Pallisco R, Saab MW, Mangione R, et al. Antioxidant-based therapies in male infertility: Do we have sufficient evidence supporting their effectiveness?. Antioxidants 2021; 10(2):220.
  28. Majzoub A, Agarwal A. Antioxidant therapy in idiopathic oligoasthenoteratozoospermia. Indian Journal of Urology 2017; 33(3):207-14.
  29. Symeonidis EN, Evgeni E, Palapelas V, Koumasi D, Pyrgidis N, Sokolakis I, et al. Redox balance in male infertility: Excellence through moderation—“Μέτρον ἄριστον”. Antioxidants 2021; 10(10):1534.
  30. Parivar K, Nasr EM, Hayati RN. Evaluation of Sperm Quality and Oxidative Stress Level in Asthenoteratozoospermia Men by N-Acetylcysteine Treatment; 2020:27-38.
  31. Perros C. Oxidative stress challenges during the sperm cryopreservation in dogs. J. Vet. Androl 2017; 2:1-7.
  32. Saleh R, Assaf H, Abd El Maged W, Fawzy M, Elsuity MA. Positive effects of in-vitro Myo-inositol supplementation of cryopreserved human sperm on the outcome of cryopreservation: A randomized controlled trial. Fertility and Sterility 2017; 108(3):e309.
  33. Chhetri DR. Myo-inositol and its derivatives: their emerging role in the treatment of human diseases. Frontiers in pharmacology 2019; 10:1172.
  34. Barbagallo F, La Vignera S, Cannarella R, Aversa A, Calogero AE, Condorelli RA. Evaluation of sperm mitochondrial function: a key organelle for sperm motility. Journal of Clinical Medicine 2020; 9(2):363.
  35. Hinton BT, White RW, Setchell BP. Concentrations of myo-inositol in the luminal fluid of the mammalian testis and epididymis. Reproduction 1980; 58(2):395-9.
  36. Colone M. Inositol activity in oligoasthenoteratospermia--an in vitro study. European Review for Medical and Pharmacological Sciences; 2010.
  37. Calogero AE, Gullo G, La Vignera S, Condorelli RA, Vaiarelli A. Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double‐blind randomized placebo‐controlled study. Andrology 2015; 3(3):491-5.
  38. Arora M, Dzubay SK, Huntington A, Prewitt KC, Andrea SB. Cannabis use & female infertility: A cross sectional analysis of the National Health and Nutrition Examination Survey, 2013–2018. Annals of Epidemiology 2025; 104:1-7.
  39. Condorelli RA, La Vignera S, Mongioì LM, Alamo A, Calogero AE. Diabetes mellitus and infertility: different pathophysiological effects in type 1 and type 2 on sperm function. Frontiers in endocrinology 2018; 9:268.
  40. Azizi M, Cheraghi E, Soleimani Mehranjani M. Effect of Myo‐inositol on sperm quality and biochemical factors in cryopreserved semen of patients with Asthenospermia. Andrologia 2022; 54(10):e14528.
  41. Osman R, Lee S, Almubarak A, Han JI, Yu IJ, Jeon Y. Antioxidant effects of myo-inositol improve the function and fertility of cryopreserved boar semen. Antioxidants 2023; 12(9):1673.
مجله زنان، مامایی و نازایی ایران
دوره 28، شماره 12
اسفند 1404
صفحه 92-109

فایل ها

هم رسانی

ارجاع به این مقاله

آمار